Esium D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting mucosal healing and symptom relief in acid-related conditions. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance. Esium D Capsule SR is indicated for patients requiring both acid suppression and prokinetic effects to alleviate symptoms associated with GERD, erosive esophagitis, and functional dyspepsia. It should be administered as per physician’s guidance, with caution in patients with hepatic impairment or known hypersensitivity to either component. Common adverse effects may include headache, dry mouth, abdominal discomfort, or diarrhea. This combination therapy offers a comprehensive approach by addressing both acid hypersecretion and impaired gastric motility, thereby improving clinical outcomes in upper gastrointestinal disorders.